Merrimack Pharmaceuticals, Inc. (MACK)
Stock Price:
$3.61 USD
0.00 (0.00%)
Updated Aug 13, 2020 4:00 PM EDT - Market open
After-hours: $3.66 +0.05 (1.39%) Aug 13, 4:22 PM
Key Info
| Market Cap |
48.30M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
1.64M |
| Shares Out |
13.38M |
| EPS (ttm) |
0.12 |
| PE Ratio |
30.08 |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 13, 2020 |
| Last Price |
$3.61 |
| Previous Close |
$3.61 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
- |
| Day's Range |
3.24 - 3.63 |
| Day's Volume |
0 |
| 52-Week Range |
1.49 - 7.09 |
More Stats
| Market Cap |
48.30M |
| Enterprise Value |
32.57M |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
13.38M |
| Float |
8.23M |
| EPS (basic) |
0.12 |
| EPS (diluted) |
0.12 |
| FCF / Share |
-0.66 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
3.32% |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
489,232 |
| Short Ratio |
23.10 |
| Short % of Float |
4.87% |
| Beta |
2.39 |
| PE Ratio |
30.08 |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.71 |
| Revenue |
n/a |
| Operating Income |
-4.04M |
| Net Income |
1.64M |
| Free Cash Flow |
-8.83M |
| Net Cash |
15.74M |
| Net Cash / Share |
1.18 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-18.88% |
| ROE |
-7.99% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
4.00
Current: $3.61
High
4.00
Target: 4.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | - | 103 | 47.79 | 48.92 | 34.22 | 20.31 |
| Revenue Growth | - | - | - | - | - | 115.03% | -2.32% | 42.98% | 68.51% | - |
| Gross Profit | - | - | - | - | - | 103 | 47.79 | 48.92 | 34.22 | 20.31 |
| Operating Income | -22.36 | -65.58 | -95.77 | -147 | -145 | -66.26 | -121 | -92.74 | -80.87 | -49.18 |
| Net Income | -17.33 | -40.51 | 472 | -152 | -148 | -83.29 | -131 | -91.28 | -79.22 | -50.10 |
| Shares Outstanding | 13.35 | 13.34 | 13.23 | 12.53 | 11.14 | 10.44 | 9.89 | 7.28 | 1.13 | 1.10 |
| Earnings Per Share | -1.30 | -3.03 | 35.67 | -12.11 | -13.29 | -8.00 | -13.20 | -12.80 | -76.70 | -55.70 |
| Dividend Per Share | 2.00 | - | 10.55 | - | - | - | - | - | - | - |
| Operating Cash Flow | -31.37 | -65.59 | -126 | -170 | -105 | -34.81 | -95.18 | -79.82 | -52.82 | -26.37 |
| Capital Expenditures | 2.03 | -0.04 | 0.18 | -2.64 | -11.90 | -6.04 | -9.86 | -3.19 | -3.75 | -5.00 |
| Free Cash Flow | -29.34 | -65.63 | -126 | -173 | -117 | -40.84 | -105 | -83.01 | -56.57 | -31.37 |
| Cash & Equivalents | 16.58 | 71.86 | 94.22 | 22.30 | 186 | 125 | 156 | 111 | 50.84 | 31.09 |
| Total Debt | - | 14.87 | - | 217 | 258 | 120 | 112 | 39.86 | 0.05 | 0.49 |
| Net Cash / Debt | 16.58 | 56.99 | 94.22 | -195 | -71.36 | 4.71 | 44.21 | 70.73 | 50.79 | 30.60 |
| Assets | 20.08 | 88.54 | 117 | 81.48 | 235 | 159 | 192 | 149 | 85.30 | 57.58 |
| Liabilities | 2.77 | 29.72 | 21.04 | 334 | 419 | 261 | 236 | 155 | 107 | 85.26 |
| Book Value | 17.31 | 58.82 | 96.28 | -250 | -184 | -102 | -43.80 | -6.61 | -291 | -221 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Merrimack Pharmaceuticals, Inc. |
| Country |
United States |
| CEO |
Gary L. Crocker |
Stock Information
| Ticker Symbol |
MACK |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: MACK |
| IPO Date |
March 29, 2012 |
Description
Merrimack Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5. The company has a collaboration and license agreement with Ipsen S.A. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is based in Cambridge, Massachusetts.